Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Description

Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.

Conditions

Neovascular Age-related Macular Degeneration

Talk to us

Study Overview

On this page

Study Details

Study overview

Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Condition
Neovascular Age-related Macular Degeneration
Intervention / Treatment

-

Contacts and Locations

Glendale

Kent W. Small, MD, AMC, Glendale, California, United States, 91203-1971

Loma Linda

Loma Linda University, Loma Linda, California, United States, 92354

Oakland

East Bay Retina Consultants, Inc., Oakland, California, United States, 94609

Palm Desert

Southern California Desert Retina Consultants, Inc., Palm Desert, California, United States, 92211

Sacramento

UC Davis Health Eye Center, Sacramento, California, United States, 95817

Torrance

Macula Retina Vitreous Institute, Torrance, California, United States, 90503

Walnut Creek

Bay Area Retina Associates A Medical Group, Walnut Creek, California, United States, 94598

Manchester

Retina Consultants, Manchester, Connecticut, United States, 06042

Fort Myers

National Ophthalmic Research Institute, Fort Myers, Florida, United States, 33912

Fort Myers

National Ophthalmic Research Institute, Fort Myers, Florida, United States, 33912

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥ 50 years
  • * Have the capacity to consent on his/her own behalf
  • * Able to successfully and independently complete at least one self-scanning session on the Home OCT device located at the enrolling clinical site
  • * Willing to perform once daily Home OCT monitoring tests for 2 years without significant interruption (such as travel of more than 14 days)
  • * Best corrected E-ETDRS visual acuity ≥24 ETDRS letters (approximately 20/320 or better (Snellen))
  • * Previously untreated, active macular neovascularization (MNV) lesion (i.e., any intraretinal or subretinal fluid within the center 3x3 mm area on OCT) secondary to age-related macular degeneration
  • * ≥ 1 intermediate drusen (\>63 microns) in either eye OR late AMD (MNV or macular atrophy) in the contralateral eye
  • * Previous treatment for MNV (intravitreal injection of any anti-VEGF or anti-VEGF/anti-Ang2 agent, or any other AMD therapy)
  • * Prior treatment with intravitreal injection of any anti-VEGF or anti-VEGF/anti-Ang2 agent or with macular laser for any indication
  • * Treatment with intravitreal corticosteroids within the last 6 months
  • * Any condition that may preclude adequate imaging of the macula (e.g., dense cataract or other media opacity, severe ptosis)
  • * MNV due to other causes, such as ocular histoplasmosis, central serous choroidopathy, or pathologic myopia

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jaeb Center for Health Research,

Study Record Dates

2027-07-30